Voyager Therapeutics (VYGR) PT Lowered to $8 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
May 13, 2024 4:01 PM EDT- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimers disease; expect to begin single ascending dose trial in the coming weeks -
- Development candidates selected for Neurocrine-partnered GBA1 and Friedreichs Ataxia gene therapy programs; potential for three gene therapies, including SOD1-ALS, to enter the clinic in 2025 -
- Appointed neurology clinical development expert Toby Ferguson, M.D., Ph.D., as Chief Medical Officer -
- Strong cash position of approximately $400 million as of March 31, 2024;... More
